Therapeutic interventions targeting the AhR/IL-22 axis may offer novel avenues for the management of ulcerative colitis, potentially enhancing autophagic processes and improving intestinal health outcomes (99, 100). The gene discussed is IL22; the disease is ulcerative colitis.